SEC Fo	orm 4
--------	-------

П

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Chec	k this box if no longer subject to
Section	on 16. Form 4 or Form 5
obliga	ations may continue. See
Instru	ction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

			or Section So(n) of the investment company Act of 1340						
1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol <u>PDL BIOPHARMA, INC.</u> [PDLI]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
DAWES KAREN A (Last) (First) (Middle) C/O PDL BIOPHARMA, INC. 34801 CAMPUS DRIVE				X	Director	10% Owner			
		()	3. Date of Earliest Transaction (Month/Day/Year) 06/20/2007		Officer (give title below)	Other (specify below)			
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	6. Individual or Joint/Group Filing (Check Appli Line)				
(Street)				X	Form filed by One Re	porting Person			
FREMONT	CA	94555			Form filed by More th Person	an One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)			4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		3,000		(1)	06/20/2014	Common Stock	3,000	\$0	3,000	D	
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		3,000		(1)	06/20/2014	Common Stock	3,000	\$0	3,000	D	
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		3,000		(1)	06/20/2014	Common Stock	3,000	\$0	3,000	D	
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		3,000		(1)	06/20/2014	Common Stock	3,000	\$0	3,000	D	
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		15,000		(2)	06/20/2014	Common Stock	15,000	\$0	15,000	D	
Stock Option (Right to Buy)	\$23.89	06/20/2007		A		5,000		(3)	06/20/2014	Common Stock	5,000	\$0	5,000	D	

Explanation of Responses:

1. This option will vest with respect to 250 shares on July 20, 2007 and with respect to 250 of the shares monthly thereafter.

2. This option will vest with respect to 1,250 shares on July 20, 2007 and with respect to 1,250 of the shares monthly thereafter.

3. This option will vest with respect to approximately 417 shares on July 20, 2007 and with respect to approximately 417 of the shares monthly thereafter.

Remarks:

/s/ Francis Sarena by Francis Sarena, Attorney-in-Fact for Karen A. Dawes

** Signature of Reporting Person

06/22/2007

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.